ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1884

Which Cell Pattern in Immunological Bronchoalveolar Lavage (BAL) Is Associated with a High-resolution Computer Tomography (HRCT) Pattern at the Onset of Inflammatory Rheumatic Disease with Interstitial Lung Disease?
Abstract Number: 1885

The Frequency and Importance of Subchondral Radius Cysts in Rheumatoid Arthritis Patients Under B/tsDMARDs
Abstract Number: 1886

Costotransverse Joint Ankylosis and Association with Syndesmophyte Progression in Patients with Radiographic Axial Spondyloarthritis
Abstract Number: 1887

Total-body PET Quantitative Biomarkers Reveal Key Differences in Enthesitis Between Rheumatoid and Psoriatic Arthritis Patients
Abstract Number: 1888

Solving the Final Puzzle of Gout Detection in DECT via Machine Learning-Based Mitigation of Pseudolesion-Related Challenges: Enhancing Diagnostic Accuracy
Abstract Number: 1889

Utility of a Diagnostic Algorithm in the Assessment of Large Vessel Vasculitis
Abstract Number: 1890

Use of Artificial Intelligence to Diagnose Polymyalgia Rheumatica on 18F-FDG Whole Body PET/CT in Patients with Atypical Clinical Features
Abstract Number: 1891

Effect of Apremilast on Disease Interception in Patients with Psoriasis at Increased Risk of Developing PsA – Results of the Prospective Interventional Epos Trial
Abstract Number: 1892

Sacroiliac Bone Marrow Oedema on Postpartum MRI Does Not Result in Significant SpA-like Structural Lesions: Results of a 5-year Follow-up Study
Abstract Number: 1893

Abnormalities Detected with [18F]-FDG-PET/CT Imaging in VEXAS Syndrome
Abstract Number: 1894

3-Dimensional Regional Variation in Inter-rater Reliability of Bone Marrow Lesion Scoring in the Knee
Abstract Number: 1895

Comparative Analysis of Existing Tools in Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis: Exploring the Inadequacies
Abstract Number: 1896

Systematic Review and Analysis of Mobile Apps for Rheumatoid Arthritis Using the Mobile Application Rating Scale
Abstract Number: 1897

In Pursuit of Excellence: Improving Systemic Sclerosis Quality of Care
Abstract Number: 1898

Patient After Visit Instructions at a University Rheumatology Outpatient Clinic: Do They Make a Difference?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].